Recent studies have reported that the activity of the calcium-dependent protease calpain is increased in acute inflammatory processes of the cardiovascular system. Because diabetes is associated with vascular inflammation, we hypothesized that increased calpain activity in response to hyperglycemia may play a role in diabetic cardiovascular disease. The effects of calpain inhibition on leukocyte-endothelium interactions induced by hyperglycemia were examined by intravital microscopy. Intraperitoneal administration of the selective calpain inhibitor benzyloxycarbonyl-leucyl-leucinal (5 µmol/L) prevented the up-regulation of leukocyte-endothelium interactions in response to 25 mmol/L D-glucose via a nitric oxidedependent mechanism. Furthermore, treatment of rats with D-glucose significantly decreased basal endothelial NO release in mesenteric post-capillary venules, a phenomenon prevented by inhibition of calpain activity. Immunoprecipitation studies revealed that glucose induces loss of NO via a calpain-dependent decrease in the association of hsp90 with endothelial nitric oxide synthase. In addition, inhibition of calpain activity decreased endothelial cell surface expression of the pro-inflammatory adhesion molecules ICAM-1 and VCAM-1 during hyperglycemia. These data demonstrate that calpains contribute to important inflammatory events during hyperglycemia and that pharmacological inhibition of calpain activity attenuates leukocyteendothelium interactions and preserves eNOS function.
D
iabetes is associated with significantly increased risk of cardiovascular disease, including atherosclerosis, coronary artery disease, and microvascular complications (1) . Hyperglycemia is thought to play a key pathogenic role in the development of diabetic cardiovascular disease. High blood glucose concentrations result in endothelial dysfunction that is associated with loss of endothelium-derived nitric oxide (NO), increased vascular permeability, increased endothelial adhesiveness, and thickening of the basement membrane of blood vessels (2) . Loss of endothelial NO is very important with regard to vascular inflammation, as several studies have shown that NO inhibits the inflammatory process by downregulating leukocyte-endothelium interactions at both the cellular and molecular levels (3, 4) . We and others have reported that expression of endothelial cell adhesion molecules and leukocyte adhesiveness are increased in response to acute hyperglycemia (5, 6) . Because no theory has fully explained how hyperglycemia induces vascular dysfunction (7) , further investigation in this area is still warranted. In the present study we provide evidence demonstrating a role for calpains in the endothelial dysfunction induced by hyperglycemia.
Calpains are a family of calcium-dependent, neutral cysteine proteases involved in a number of signaling processes via limited proteolysis of substrate proteins. The two major isoforms, µ-and m-calpain, are ubiquitously expressed in vivo (8) . Recent reports suggest that calpains play an important role in several acute inflammatory disorders of the cardiovascular system, including cerebral (9) and myocardial ischemia/reperfusion (10, 11) , hemorrhage/reinfusion (12) , and endotoxic shock (13) . In addition, studies have demonstrated that the eNOS regulatory protein heat shock protein 90 (hsp90) is a substrate for calpains (14) (15) (16) . In particular, Su and Block (16) showed that calpain-mediated loss of hsp90 from the eNOS complex results in decreased eNOS activity in pulmonary artery endothelial cells exposed to hypoxia. In this regard, it has been shown that the production of nitric oxide by eNOS is dependent, among other factors and regulatory proteins, on the molecular chaperone hsp90 (17) . Hsp90 directly increases eNOS activity (18) in addition to serving as a docking site for Akt-dependent phosphorylation of eNOS (19) . However, the role of calpains in the regulation of eNOS activity and NO production during hyperglycemia has not been studied.
We hypothesized that increased calpain activity may contribute to vascular inflammation during hyperglycemia. Accordingly, we examined the effect of elevated ambient glucose on calpain activity and endothelial function. Thus, we investigated the effect of inhibition of calpain activity on leukocyte-endothelium interactions during hyperglycemia, and studied the effect of calpain inhibition on the expression of the endothelial cell adhesion molecules ICAM-1 and VCAM-1. We also studied the effect of calpain inhibition on basal NO production in the microvasculature, and on relevant posttranslational modifications of the eNOS enzyme complex.
MATERIALS AND METHODS

Calpain inhibitors
Two different calpain inhibitors were used in the present study: Calpain Inhibitor-I (N-acetylleucyl-leucyl-norleucinal) and the calpain inhibitor ZLLal (benzyloxycarbonyl-leucyl-leucinal) (Biomol Research Laboratories, Plymouth Meeting, PA), which is >100-fold more potent for calpain than proteosomal enzymes in vitro (20) . ZLLal was used at a concentration of 5 µmol/L, which has been shown to be highly selective for calpains than other proteases (20) . Both calpain inhibitors were dissolved in a final ethanol concentration of 0.01%. In control experiments, intraperitoneal injection of saline (0.9% NaCl) containing 0.01% ethanol to rats had no effect on baseline leukocyte rolling, adherence, and transmigration (data not shown).
Experimental design
This study was performed in accordance with the National Institute of Health guidelines for the use of experimental animals, and with the approval of the Thomas Jefferson University IACUC.
For all of the studies outlined below, male Sprague-Dawley rats (200-225 g) were randomly divided into one of six groups: 1) control rats injected with saline alone; 2) rats injected with saline and 25 µmol/L (100 µg/kg) Calpain Inhibitor-I; 3) rats injected with 25 mmol/L L-glucose; 4) rats injected with 25 mmol/L D-glucose; 5) rats injected with 25 mmol/L D-glucose and 25 µmol/L Calpain Inhibitor-I; and 6) rats injected with 25 mmol/L D-glucose and 5 µmol/L (18 µg/kg) ZLLal. L-glucose, D-glucose (Sigma, St. Louis, MO) and stock solutions of either Calpain Inhibitor-I or ZLLal were dissolved in a final volume of 2.5 ml saline, and administered by intraperitoneal injection 16 h prior to the experiment as described previously (5) . We have previously shown that a single intraperitoneal injection of 25 mmol/L D-glucose to rats triggers a sustained inflammatory response in the mesenteric microvasculature lasting over 24 h (5) . Intraperitoneal injection of 6 mmol/L D-glucose (normal glucose levels) to rats did not significantly change leukocyte rolling, adherence, or transmigration values (data not shown).
Western blot analysis
Highly vascularized segments of rat mesenteric tissue were harvested 16 h after intraperitoneal injection with either saline alone, 25 mmol/L D-glucose alone, or 25 mmol/L D-glucose plus 5 µmol/L ZLLal, as described previously (21) . The tissue was frozen in liquid nitrogen and homogenized using a polytron (Biospec Products, Inc., 20,000 rpm, 10 s). The extraction buffer contained: 50 mmol/L Tris, 5 mmol/L EDTA, 0.1% deoxycholic acid, 1% Triton X-100, 50 µg/ml leupeptin, 10 µg/ml AEBSF, 10 µg/ml TLCK, 10 µg/ml TPCK, and 10 µg/ml aprotinin, pH 7.4. To examine calpain activity, Western blot analysis was performed using a monoclonal antibody against αII spectrin (Chemicon International, Inc., Temecula, CA). Proteolytic cleavage of αII spectrin (240 kD) results in the formation of stable breakdown products, which can be resolved by SDS-PAGE (22) . The 145 kD breakdown product is calpain-specific and can be used as a measure of calpain activation (22) . Caspase-3 activation and IκBα levels were evaluated as markers of proteosome activity, in order to rule out possible implications of the proteosome pathway in our experimental conditions, thus assessing the specificity of the calpain inhibitor used in the study. Western blot analysis was performed by using antibodies against inactive pro-caspase-3 or the active cleaved form of caspase-3 (Chemicon International, Inc.), or IκBα (Santa Cruz Biotechnology, Santa Cruz, CA). Whole tissue extracts were used for biochemical analyses and proteins were quantified by laser densitometry (Molecular Dynamics Personal Densitometer, Piscataway, NJ).
Intravital microscopy
Rats were anesthetized by sodium pentobarbital (60 mg/kg) injected intraperitoneally. A tracheotomy was performed to keep a patent airway throughout the experiment. A polyethylene catheter was inserted into the left carotid artery to monitor mean arterial blood pressure. A loop of ileal mesentery was exteriorized through a midline incision in the abdominal wall and placed in a temperature-controlled, fluid filled Plexiglas chamber for the observation of the mesenteric microcirculation by intravital microscopy. The ileum and the mesenteric tissue were superfused throughout the experiment with a modified Krebs-Henseleit buffer warmed to 37°C and bubbled with 95% N 2 /5% CO 2 . Red blood cell velocity was measured using an optical Doppler velocimeter (Microcirculation Research Institute, College Station, TX). Red blood cell velocity (V rbc ) and venular diameter (D) were used to calculate the venular wall shear rate (g) by using the formula: g = 8(V mean /D), where V mean = V rbc /1.6 (23) . Basal values for leukocyte rolling, adherence, and transmigration were obtained using video recordings with a video camera and DVD video recorder (Panasonic, DMR-E10) according to methods described previously (24) .
To test the role of endothelial NO in the anti-inflammatory effect of calpain inhibition, additional intravital microscopy (IVM) experiments were performed in which the mesentery of rats injected with either saline or 5 µmol/L ZLLal as described above, was superfused with Krebs-Henseleit buffer containing the NOS inhibitor L-NAME (Sigma). We used 50 µmol/L L-NAME for these studies, a concentration reported to increase leukocyte-endothelium interactions by pharmacologically blocking eNOS activity in the venular endothelium (25) . L-NAME was added to the superfusion buffer after a baseline reading was taken, and leukocyte-endothelium interactions were monitored over 2 h, as described previously (25) .
Measurement of NO release from rat mesenteric venules
NO release from rat mesenteric post-capillary venules was measured by using the ISO-NO-NM microelectrode (100 nm diameter) connected to the ISO-NO Mark-II nitric oxide meter (WPI, Sarasota, FL). The microelectrode was calibrated daily by using the NO-releasing compound Snitroso-N-acetyl-penicillamine, according to the manufacturer's instructions (WPI). A computerized micromanipulator was used to position the microelectrode directly over a mesenteric post-capillary venule at a distance of ≈3 µm from the venular wall. When the microelectrode was moved away from the venular wall, the NO concentration decreased sharply, and a stable background current was obtained at a distance of 0.5-1 cm from the venular wall. The background current was then subtracted from the current measured at the venular wall to calculate the amount of NO released by the vascular endothelium. NO values were normalized according to the size of blood vessel studied and reported as nanomolar NO/1000 µm 2 vessel area.
Association of eNOS and hsp90
Immunoprecipitations were performed to study the association of endothelial nitric oxide synthase and hsp90 in tissue extracts prepared from mesenteries of rats injected with either saline alone, 25 mmol/L D-glucose, or 25 mmol/L D-glucose + 5 µmol/L ZLLal. Extracts (1000 µg protein) were incubated with anti-eNOS monoclonal antibody (BD Transduction) for 1 h followed by incubation with pre-washed Protein G-agarose (Sigma) for 2 h. The resulting pellet was washed three times, boiled in SDS sample buffer, and resolved by SDS-PAGE with immunoblot analysis by using primary antibodies against eNOS and hsp90 (Santa Cruz Biotechnology).
Immunohistochemistry
Following intravital microscopy experiments, the superior mesenteric artery and portal vein were cannulated, and the mesentery was flushed with K-H buffer to remove red blood cells, as described previously (26) . Once the venous perfusate was free of red blood cells, the bowel was perfused with ice-cold 4% paraformaldehyde for 3-5 min, and a 3-4 cm section of ileum was removed and placed in 4% paraformaldehyde for 2 h on ice. The tissue was then cut into rings, dehydrated by using graded acetone washes, and embedded in plastic (Immunobed, Polysciences Inc., Warrington, PA). Sections (4 µm thick) were cut and transferred to vectabond coated slides (Vector Laboratories, Burlingame, CA). Immunohistochemical localization of ICAM-1 and VCAM-1 was accomplished by using the avidin/biotin immunoperoxidase technique (Vectastain ABC Reagent: Vector Laboratories, Burlingame, CA), with a monoclonal antibody against either ICAM-1 or VCAM-1 (BD Transduction Laboratories, San Diego, CA) as described previously (27) . The percentage of positively staining venules was determined by examining 5-10 tissue sections per rat, with 50 venules analyzed per tissue section.
Data analysis
Data are presented as mean ± SEM, and compared by ANOVA with post hoc analysis by Fisher's corrected t-test. Probabilities of 0.05 or less were considered statistically significant.
RESULTS
Western blot analysis of αII spectrin breakdown products
Proteolytic degradation of the cytoskeletal protein αII spectrin (240 kD) results in the formation of stable breakdown products that can be detected by Western blot analysis (Fig. 1) . In particular, activated calpains induce the formation of a calpain-specific 145 kD stable spectrin breakdown product (Fig. 1A) (22) . We used this assay to test the hypothesis that hyperglycemia increases calpain activity in vivo. Densitometric analysis demonstrated a 2.2-fold increase in the production of the calpain-specific 145 kD spectrin breakdown product in the mesenteries of rats injected with 25 mmol/L D-glucose (Fig. 1B, P<0.01 ). This result demonstrates that acute hyperglycemia increases calpain activity in the highly vascularized mesenteric tissue. The formation of the 145 kD spectrin breakdown product in response to 25 mmol/L D-glucose was significantly attenuated in mesenteries of rats injected with ZLLal, demonstrating the efficacy of the calpain inhibitor ZLLal in our experimental rat model of acute elevated ambient glucose of the peritoneal cavity.
To rule out possible activation of the proteosome pathway in response to hyperglycemia in our system, we studied caspase-3 activity and IκBα levels in mesenteric tissue from all experimental groups of rats. Caspase-3 is an important proteosomal enzyme that has previously been found to be up-regulated in response to glucose in vitro (28) . IκBα is a proteosome substrate, although studies have suggested that IκBα can also be a substrate for calpains in vitro (29) . Using an antibody specific for cleaved (active) caspase-3, we found that hyperglycemia did not alter caspase-3 activity in the time frame of our experiments (16 h, Fig. 2A and B) . In addition, we found that neither acute hyperglycemia nor inhibition of calpain activity under hyperglycemic conditions changed expression levels of IκBα in whole tissue extracts (Fig. 2C) . Taken together, these results suggest lack of activation of the proteosome pathway in the early stages of the inflammatory response to hyperglycemia in vivo, thus ruling out possible non-specific proteosome effects of the calpain inhibitor ZLLal in our study.
Intravital microscopy
There were no significant differences in venular diameters, mean arterial blood pressures, or total leukocyte counts among any of the groups of rats studied. Venular diameters ranged from 28.8±1.2 to 32.1±1.0 µm and mean arterial blood pressures ranged from 132.5±3.2 to 140.7±4.0 mmHg. Total white blood cell counts ranged from 7360±412 to 7960±387 cells/mm 3 . Venular shear values were within physiologic range (30) , despite being significantly decreased in rats injected with high D-glucose concentrations (600.6±48.0 vs. 806.6±94.8 s -1 in control rats,
P<0.05).
This result is consistent with previous reports showing decreased shear values in mesenteric venules of diabetic rats (31) . Thus, under these experimental conditions, changes in leukocyte-endothelium interactions were not due to non-specific alterations of systemic hemodynamic factors or local rheologic factors.
As shown in Fig. 3 To test the role of endothelial NO in the anti-inflammatory action of calpain inhibition, we superfused the mesenteries of ZLLal treated rats with the NO synthase inhibitor L-NAME at a concentration of 50 µmol/L, which is known to induce leukocyte-endothelium interactions by pharmacologically blocking the release of NO in mesenteric venules. In contrast to the antiinflammatory effect of calpain inhibition observed in the setting of hyperglycemia, calpain inhibition failed to attenuate leukocyte-endothelium interactions evoked by blockade of the eNOS enzyme with L-NAME (Fig. 4) , indicating that the anti-inflammatory effect of calpain inhibition requires residual eNOS function to preserve endothelial NO release (see data on direct measurement of NO).
NO release in the rat mesenteric microcirculation
To study whether activated calpains modify the basal release of endothelial NO during hyperglycemia, we measured release of NO directly in mesenteric venules in vivo by using a NO-specific microelectrode (Fig. 5A) . Control rats injected with saline exhibited basal NO levels of 202.8±34.0 nM/1000 µm 2 . Intraperitoneal injection of 25 mmol/L D-glucose caused a 70% decrease in basal NO levels in the rat mesenteric microcirculation (Fig. 5B) . However, cotreatment with ZLLal completely prevented the glucose-induced loss of endothelial NO, restoring NO levels to control values (Fig. 5B ).
These data demonstrate that hyperglycemia depresses release of endothelial NO from postcapillary venules, and they also indicate a novel role for calpains in the regulation of endothelial nitric oxide synthase in the hyperglycemic environment.
Association of eNOS and hsp90
To further study the mechanisms regulating NO production during hyperglycemia, we examined the association of eNOS with hsp90, since hsp90 binding to eNOS enhances eNOS activity and NO availability (17) . Immunoprecipitation studies demonstrated significantly reduced association of eNOS and hsp90 in mesenteric tissue of rats treated with 25 mmol/L D-glucose as compared with mesenteric tissue from control rats (Fig. 5C ). Co-injection of ZLLal with Dglucose restored the association of eNOS and hsp90 (Fig. 5C) , suggesting that the loss of association in response to high glucose levels is calpain-dependent.
Immunohistochemistry
To dissect the anti-inflammatory mechanisms of calpain inhibition, we studied expression levels of ICAM-1 and VCAM-1, two endothelial cell adhesion molecules that are up-regulated in experimental hyperglycemia (6) and diabetes (32) . A low percentage of ileal venules stained positive for ICAM-1 and VCAM-1 in control rats (Fig. 6A) . Consistent with previous work (24) , rats injected i.p. with 25 mmol/L D-glucose exhibited a 3.3-fold and 5.6-fold increase in the number of ileal venules staining positive for ICAM-1 and VCAM-1, respectively (Fig. 6B) . ZLLal prevented up-regulation of both ICAM-1 and VCAM-1 on the endothelial cell surface (Fig. 6B) . Thus, activated calpains have a role in the up-regulation of proatherogenic adhesion molecules on the vascular endothelium during hyperglycemia.
DISCUSSION
The present study demonstrates that increased calpain activity plays a role in the vascular inflammation induced by hyperglycemia. We provide evidence that hyperglycemia reduces physiologic levels of endothelial nitric oxide in the microcirculation via a calpain-dependent decrease in the association of the regulatory protein hsp90 with eNOS. In addition, we demonstrate that inhibition of calpain activity during hyperglycemia attenuates leukocyteendothelium interactions via attenuated cell adhesion molecule expression, and preserves endothelial NO release.
Recent in vivo studies have reported that calpain inhibition exerts anti-inflammatory effects. Ruetten and Thiemermann (13) showed that calpain inhibitors significantly improve cardiovascular outcome and ameliorate multiple organ dysfunction during endotoxic shock. Similarly, McDonald et al. (12) reported that Calpain Inhibitor-I reduces organ injury in hemorrhaged rats. Additional studies have demonstrated a role for calpains in both cerebral and myocardial ischemia/reperfusion injury (9-11). Taken together, these studies suggest that calpains play a role in inflammatory processes of the cardiovascular system. Interestingly, increased calpain activity has been described in non-vascular diabetic tissues, such as skeletal muscle (33) and platelets (34) . Furthermore, mutation of the gene-encoding calpain 10 (CAPN10) has recently been associated with an increased prevalence of Type II diabetes in humans (35) , highlighting the importance of calpains in the regulation of fundamental signaling pathways in diabetes.
In light of these findings, we sought to investigate the role of calpains in the vascular inflammation associated with hyperglycemia. Although much work has been done in recent years to determine the underlying causes of diabetic vascular complications (7), the mechanisms by which hyperglycemia causes endothelial dysfunction remain only partially understood. Increased oxidative stress and loss of endothelial NO is considered a key mechanism by which high glucose disrupts the homeostasis of endothelial cells. Endothelial NO modulates vascular permeability (36) , inhibits platelet aggregation (37) , and inhibits leukocyte-endothelium interactions (3). During hyperglycemia, increased production of reactive oxygen species associated with primary or secondary loss of endothelial nitric oxide may contribute to diabetic vascular disease.
Leukocyte-endothelium interactions are an important aspect of the inflammatory process. The vascular endothelium directs leukocytes to sites of vascular injury in response to inflammatory stimuli in order to prevent infection. While this inflammatory process is necessary to avert infectious diseases, an abnormal initiation of the inflammatory response during pathologic conditions, such as hyperglycemia and diabetes, may cause damage to blood vessels and surrounding tissue due to the production of toxic mediators (i.e., reactive oxygen species and cytokines) by the dysfunctional endothelium or by activated leukocytes (38) . In this regard, recent studies have shown sequestration of leukocytes in the diabetic retinal microcirculation, leading to vascular damage (39) . Furthermore, pathologic leukocyte trafficking may have a role in the development of macrovascular disease. It has been suggested that increased leukocyte trafficking in the microcirculation of the vasa vasorum may contribute to the pathogenesis of atherosclerosis (40) . In addition, recent studies have implicated chronic inflammation as a strong independent risk factor for the development of atherosclerosis, and inflammatory markers, such as c-reactive protein, are now recommended as a measure of cardiovascular disease risk (41, 42) .
In the present study, we found evidence that the inflammatory signal produced by acute elevation of ambient glucose increases calpain activity and causes endothelial dysfunction. Preservation of endothelial NO availability could account for the beneficial effects of calpain inhibition on glucose-induced vascular inflammation. To address this issue, we directly measured NO levels in the microcirculation in vivo during hyperglycemia. We show evidence that elevated ambient glucose significantly reduces basal NO levels in vivo in the microcirculation. To our knowledge this is the first study to directly show that elevated ambient glucose significantly reduces basal NO levels in vivo in the microcirculation, and that inhibition of calpain activity preserves NO release during hyperglycemia. This finding is in agreement with previous studies demonstrating that hyperglycemia and diabetes uncouple eNOS activity (43) , and decrease endotheliumdependent vessel relaxation (44) .
One mechanism that may explain the relationship between inhibition of calpain activity and preservation of endothelial NO in hyperglycemia is altered post-translational regulation of endothelial nitric oxide synthase. A recent study (16) demonstrated that inhibition of calpain activity increases eNOS activity in endothelial cells exposed to hypoxia via inhibited degradation of the molecular chaperone hsp90, a known calpain substrate (14) . Hsp90 normally increases eNOS activity by stabilizing the enzyme complex, and inhibition of hsp90 activity or loss of hsp90 from the eNOS complex results in attenuated NO production (17) . We found that the antiinflammatory effect of calpain inhibition is indeed NOS-dependent, as inhibition of calpain activity failed to block leukocyte-endothelium interactions in response to pharmacological blockade of nitric oxide synthase activity. This result suggests that residual eNOS function is necessary for the anti-inflammatory effect of calpain inhibition. In addition, we found that hsp90 association with eNOS is decreased in mesenteries exposed to elevated ambient glucose, and this association is restored following calpain inhibition. These data support the hypothesis that increased calpain activity in response to high glucose levels inhibits endothelial NO production by disrupting the association of eNOS and hsp90.
Loss of NO in the microcirculation can result in up-regulation of proadhesive cell adhesion molecules, such as ICAM-1 and VCAM-1 (4). In this regard, it has been shown that nitric oxide donors inhibit cell surface expression of cell adhesion molecules via stabilization of NFκB, independent of increased IκB degradation (45) . In addition, a recent study has demonstrated sustained activation of NFκB in the absence of IκB degradation in diabetic patients (46) . Overall, these results are in agreement with our finding of unchanged levels of IκBα in our experimental setting. However, it should be noted that in the present study IκBα levels were measured in whole tissue extracts. Indeed, it has also been shown that IκB may translocate into the nucleus where it specifically displaces the p50/p65 complex of NF-κB (47). Nuclear-bound IκBα could be protected from proteolytic degradation since proteolytic degradation of IκB occurs in the cytosol (47) . Thus, further studies are needed to elucidate the impact of hyperglycemia and calpain activity on the regulation of IκBα kinetics and NFκB activity in the diabetic vasculature.
In conclusion, we have demonstrated that calpain activity is increased in response to elevated glucose levels, and that inhibition of calpain activity attenuates vascular inflammation induced by high glucose via a NO-dependent mechanism. Our findings uncover a novel signaling pathway implicated in the pathophysiology of diabetic vascular disease. 
